Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Bowman Cox
Tens of thousands of listed drugs could be barred if manufacturers do not update their records.
ICH prepares to lift veil on global regulatory harmonization progress as it hires trainers to speed up the process.
Democratic senators push data-challenged gene therapy into maw of drug pricing debate as they press acting commissioner Sharpless to bring the hammer down on Novartis, but also question US FDA's decision to withdraw the proposed rule last year.
More unannounced inspections abroad would warm Senate Finance Committee chairman to President Trump's drug importation plan.
After years of Mylan’s “one quality standard,” the merger with Pfizer Upjohn brings another. Which will prevail? Which should prevail?
Industry complained draft guidance would have made manufacturing establishment information harder to report, not easier.